Cartherics is pleased to share Dr Ian Nisbet’s presentation at the Emergence Investment Conference in Sydney, where he outlined the Company’s strategy, progress and vision for transforming women’s health through pioneering cellular immunotherapies.

Speaking to an audience of investors and industry leaders, Dr Nisbet highlighted Cartherics’ unique focus on developing off-the-shelf cell therapies designed specifically to address serious conditions affecting women. He detailed how the Company has built a fully integrated discovery-to-clinic engine over the past decade – spanning discovery, pre-clinical development, GMP manufacturing, and clinical translation – enabling efficient progression of programs from concept through to the clinic.

The presentation also explored Cartherics’ lead programs in ovarian cancer and endometriosis, two areas of significant unmet medical need. By combining proprietary technology platforms with deep expertise in immunology and cell engineering, Cartherics is advancing a growing pipeline of innovative therapies designed to deliver scalable, accessible treatment options for patients.

Dr Nisbet discussed the strength of the Company’s scientific foundations, manufacturing capabilities and strategic partnerships, as well as the broader market opportunity in women’s health – an area historically underserved in therapeutic innovation. He also outlined the milestones ahead as Cartherics continues to progress its pipeline and expand its clinical and commercial potential.

We invite you to watch the full presentation to learn more about Cartherics’ differentiated approach and long-term vision.

Watch the presentation here: https://www.youtube.com/watch?v=5tXocF_sg6w